This year, China promulgated the "Regulations of the State Council on the Handling of Foreign-Related Intellectual Property Disputes", and the State Drug Administration issued the "Implementation Measures for the Protection of Drug Trial Data (Trial, Draft for Comments)",

and new changes have also occurred in the policies on pharmaceutical trade secrets.

At the same time, with the changes in the international situation, more and more pharmaceutical companies are paying more attention to intellectual property rights.

This summit will focus on the changes in pharmaceutical intellectual property rights in China, the United States, Europe, Asia-Pacific and other places.

Part of Speakers：

ü     Director of Chemical Appeals Division I, Reexamination and Invalidation Division, NMPA

ü     Patent Legal Director，Johnson & Johnson

ü     Global Head of IP，Sanofi

ü     VP&Legal Director, Roche China

ü     Partner, Sonderhoff & Einsel Law and Patent Office

ü     Partner, Liu Shen & Associates

ü     Vice President of intellectual property, LUYE PHARMA

ü     Director of Intellectual Property Management Center，Jiangsu Hengrui Pharmaceuticals Co., Ltd

ü     Intellectual Property Director,Jiangsu Nhwa Pharmaceutical Co., Ltd.

ü     Head of IP, Juntuo Biomedical Technology

ü     Intellectual Property Director,Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.

ü     Partner, King & Wood Mallesons

ü     Assistant Director-General, WIPO

ü     Deputy Director of IP Department, Qilu Pharmaceutical

ü     Partner, Han Kun LLP

ü     VP of Business Development, TYK Medicines, Inc

ü     IP Director, Eddingpharm

Agenda Overview:

Day 1 Morning：

       Interpretation of biomedical intellectual property laws and policies under the new situation

    Patent protection in the biomedical field under the new patent law

    The particularity of patent applications in the biological field

    Comparison of early dispute resolution systems for biopharmaceutical patents in China and the US

    International progress in drug trial data protection and related systems

Day 1 Afternoon：

       R&D innovation and patent protection in the fields of biotechnology and medicine

    Innovative patent research and development trends in the field of biotechnology

    Exploration and development of patent application technologies in the fields of gene editing and genetic engineering technologies

    Opportunities and challenges brought by patent cliff

    Determination and cultivation of high-value patents

    Pharmaceutical enterprise trade secret protection and infringement risk prevention

Day 2 Morning：

       Trends in biomedical R&D and patent protection from a global perspective

    Global biosimilar patent litigation and marketing review

    Extended means of protection for pharmaceutical products – SPC

    The impact of the US S.150 bill on the marketing of generic drugs and biosimilar drugs

    Practical Strategies for European Medical Invention Patent Application and Patent Validation

Day 2 Afternoon：

      The balance and game between patent layout and management of innovative drugs and generic drugs

    Patent layout of pharmaceutical companies and industry cross-border overseas strategy

    Patent avoidance and challenges in current generic drug research and development

    The dilemma and development path of patent protection for indications after drug marketing

    Drug new use patent layout strategy and authorization confirmation disputes

Partial inviting Companies & Institutions :